NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free lgnd Stock Alerts $73.10 +1.83 (+2.57%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$71.29▼$73.4250-Day Range$68.64▼$89.2052-Week Range$49.24▼$94.57Volume109,733 shsAverage Volume211,091 shsMarket Capitalization$1.29 billionP/E Ratio26.58Dividend YieldN/APrice Target$116.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ligand Pharmaceuticals alerts: Email Address Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside59.1% Upside$116.33 Price TargetShort InterestBearish5.28% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.97Based on 4 Articles This WeekInsider TradingSelling Shares$153,034 Sold Last QuarterProj. Earnings Growth16.84%From $2.91 to $3.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.91 out of 5 starsMedical Sector26th out of 938 stocksPharmaceutical Preparations Industry13th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $116.33, Ligand Pharmaceuticals has a forecasted upside of 59.1% from its current price of $73.10.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.28% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 14.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 3.3 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest6 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $153,034.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 16.84% in the coming year, from $2.91 to $3.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 26.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 26.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 270.19.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesMarch 17, 2024 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Stephen L. Sabba Sells 1,893 SharesMarch 28, 2024 | finance.yahoo.comLigand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 27, 2024 | msn.comLigand Pharmaceuticals gains amid bullish investor pitchMarch 16, 2024 | finance.yahoo.comLGND Apr 2024 70.000 putMarch 16, 2024 | finance.yahoo.comLGND Apr 2024 110.000 callMarch 6, 2024 | uk.finance.yahoo.comLigand Pharmaceuticals Incorporated (LGND)March 5, 2024 | businesswire.comLigand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare ConferenceMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 4, 2024 | businesswire.comLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 3, 2024 | ca.finance.yahoo.comLGND Aug 2024 110.000 callMarch 3, 2024 | ca.finance.yahoo.comLGND Apr 2024 90.000 callFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)February 28, 2024 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comLigand Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsFebruary 27, 2024 | msn.comWhy Is Ligand Pharmaceuticals Stock Trading Higher Today?February 27, 2024 | finance.yahoo.comLigand Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Solid Earnings Amidst Operational TransformationFebruary 27, 2024 | businesswire.comLigand Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | benzinga.comLigand Pharmaceuticals's Earnings: A PreviewFebruary 26, 2024 | msn.comLigand Pharmaceuticals Q4 2023 Earnings PreviewFebruary 23, 2024 | finance.yahoo.comLGND Mar 2024 65.000 putFebruary 22, 2024 | msn.comEsai gets Japanese approval for epilepsy drug using Ligand technologyFebruary 22, 2024 | businesswire.comLigand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®February 20, 2024 | finance.yahoo.comWhy Ligand Pharmaceuticals (LGND) Dipped More Than Broader Market TodayFebruary 16, 2024 | businesswire.comLigand Pharmaceuticals Expands Senior Leadership Team with Two Key HiresFebruary 13, 2024 | finance.yahoo.comLigand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024See More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$116.33 High Stock Price Target$144.00 Low Stock Price Target$95.00 Potential Upside/Downside+59.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.75 Trailing P/E Ratio26.58 Forward P/E Ratio25.12 P/E GrowthN/ANet Income$52.15 million Net Margins37.80% Pretax Margin48.48% Return on Equity11.98% Return on Assets10.27% Debt Debt-to-Equity RatioN/A Current Ratio14.15 Quick Ratio12.72 Sales & Book Value Annual Sales$131.31 million Price / Sales9.85 Cash Flow$5.13 per share Price / Cash Flow14.25 Book Value$40.39 per share Price / Book1.81Miscellaneous Outstanding Shares17,700,000Free Float15,864,000Market Cap$1.29 billion OptionableOptionable Beta1.02 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Todd C. Davis Ph.D. (Age 63)CEO & Director Comp: $743.49kMr. Matthew E. Korenberg (Age 49)President & COO Comp: $760.99kMr. Octavio Espinoza (Age 53)Chief Financial Officer Comp: $457.19kMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Comp: $480.16kMr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More ExecutivesKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDMannKindNASDAQ:MNKDInnovivaNASDAQ:INVADynavax TechnologiesNASDAQ:DVAXPraxis Precision MedicinesNASDAQ:PRAXView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 450 shares on 3/22/2024Ownership: 0.010%Vanguard Group Inc.Bought 24,653 shares on 3/11/2024Ownership: 10.602%Fisher Asset Management LLCBought 16,035 shares on 3/5/2024Ownership: 0.279%Stephen L SabbaSold 1,893 sharesTotal: $140,649.90 ($74.30/share)Wellington Management Group LLPBought 14,687 shares on 3/5/2024Ownership: 0.083%View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 12-month price objectives for Ligand Pharmaceuticals' stock. Their LGND share price targets range from $95.00 to $144.00. On average, they anticipate the company's stock price to reach $116.33 in the next twelve months. This suggests a possible upside of 59.1% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2024? Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of 2024. Since then, LGND stock has increased by 2.4% and is now trading at $73.10. View the best growth stocks for 2024 here. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Tuesday, February, 27th. The biotechnology company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.55. The biotechnology company earned $28.10 million during the quarter, compared to the consensus estimate of $24.54 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 11.98% and a net margin of 37.80%. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $4.25 to $4.75 for the period, compared to the consensus estimate of $4.28. The company issued revenue guidance of $130 million to $142 million, compared to the consensus revenue estimate of $137.66 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.82%), Vanguard Group Inc. (10.60%), Dimensional Fund Advisors LP (3.81%), Stephens Investment Management Group LLC (3.80%), Villere ST Denis J & Co. LLC (2.47%) and Pacer Advisors Inc. (1.88%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGND) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.